AUTHOR=Guo Zhi , Zhu Jie , Wang Jun , Wang Liang , Tang Feifei , Huang Huiqiang , Xia Zhongjun , Liu Liqiong , Wang Danyu , Zhong Nan , Zhou Huanhuan , Zhou Zhaogui , Dai Wei , Xu Xiaojun , Zhou Hao , Deng Lijuan , Meng Jingye , Sun Zhiqiang , Shao Liang , Cao Yu J. , Liu Yansong , Qu Rong , Li Guowei , Chen Peng , Zhang Hongyan , Liang Jing , Li Yuhua , Liu Jiajun , Xu Zishan , Sung Inda Soong , Xiang Xiaochen , Wu Qingming , Wang Qiang 

TITLE=Chinese expert consensus on the application of intravenous immunoglobulin in hematological diseases

JOURNAL=Frontiers in Medicine

VOLUME=Volume 12 - 2025

YEAR=2025

URL=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1544025

DOI=10.3389/fmed.2025.1544025

ISSN=2296-858X

ABSTRACT=Intravenous immunoglobulin (IVIG), first developed for the treatment of patients with antibody deficiencies, is now widely used in clinical practice, especially in hematological and immune system diseases, and its application in hematological oncology chemotherapy, cellular immunotherapy and hematopoietic stem cell transplantation (HSCT) is becoming more and more common. The Chinese Collaborative Group for Infection Immunology and Microecology Research Translation Collaborative Group organized relevant experts to discuss and propose the “Chinese expert consensus on the application of intravenous immunoglobulin in hematological diseases,” which was formulated based on the progress of research on the application of IVIG in blood diseases, and provides a basis for the standardization of the use of IVIG in hematologic disorders.